Data from pharmawand - Curated by Toby Galbraith - Date added 05 July 2012

Takeda and Millennium Oncology have begun a Phase III development programme for ixazomib citrate (MLN 9708), the first oral proteasome inhibitor to enter clinical trials for Multiple Myeloma and to be a possible successor to the Velcade. The trial is TOURMALINE-MM1 which will assess MLN 9708 in patients with relapsed and/or refractory Multiple Myeloma at sites in North and South America, Europe and the Asia-Pacific region. A once weekly dose will be administered in combination with lenalidomide and dexamethasone therapy and compared with placebo plus the latter two drugs against the primary endpoint of progression-free survival.Ixazomib has improved and broader activity and pharmacokinetics compared with Velcade which is intravenously administered whereas Ixazomib is orally administered.


You will need to login, to leave a comment.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.


See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis


See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation

Related Content